Status: Recruiting
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab (anti-PD-1 antibody).
Participants needed: 130
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Sairopa B.V.Updated: Dec 17, 2025Locations: 7
Eligibility criteria
Male or female aged ≥18 years [+6]
Escalation Phase: Patients that suffer from melanoma, brain tumors, glioblastoma... [+19]